Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$31.38 USD

31.38
3,352,548

-0.02 (-0.06%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $31.38 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kanishka Das headshot

Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

by Kanishka Das

Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.

Zacks Equity Research

Catalyst Pharmaceutical (CPRX) is a Top-Ranked Momentum Stock: Should You Buy?

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Marinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic Disorder

by Zacks Equity Research

The FDA approves Marinus' (MRNS) Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. The company's shares gain following the announcement.

Zacks Equity Research

Catalyst (CPRX) Q4 Earnings Lag Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Catalyst's (CPRX) fourth-quarter 2021 earnings miss estimates while revenues slightly beat the mark.

Zacks Equity Research

Catalyst Pharmaceutical (CPRX) Q4 Earnings Lag Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of -25% and 0.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is AmerisourceBergen (ABC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AmerisourceBergen (ABC) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Zacks Equity Research

Molina Healthcare (MOH) Up 32% in a Year: Is More Upside Left?

by Zacks Equity Research

Continued revenue growth, well-performing Medicaid and Medicare businesses, expense saving initiatives and solid cash balance continue to drive Molina Healthcare (MOH).

Zacks Equity Research

Allogene's (ALLO) CAR T Therapy Gets Fast Track Designation

by Zacks Equity Research

The FDA grants a Fast Track designation to Allogene's (ALLO) early-stage CAR T therapy candidate, ALLO-316, for treating advanced or metastatic clear cell RCC.

Zacks Equity Research

Catalyst (CPRX) Skyrockets 110% Over a Year: Here's Why

by Zacks Equity Research

Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.